首页> 外文OA文献 >Effectiveness of a 23-valent pneumococcal polysaccharide vaccine for the prevention of pneumococcal pneumonia in the elderly with chronic respiratory diseases: a case–control study of a single center
【2h】

Effectiveness of a 23-valent pneumococcal polysaccharide vaccine for the prevention of pneumococcal pneumonia in the elderly with chronic respiratory diseases: a case–control study of a single center

机译:慢性呼吸系统疾病预防肺炎球菌肺炎肺炎肺炎肺炎肺炎的效果:单一中心的病例对照研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Abstract Background The effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in preventing pneumococcal pneumonia has been controversial. Methods To evaluate the effectiveness of the PPSV23 in elderly outpatients with chronic respiratory diseases, we carried out a case–control study, including 4128 outpatients aged ≥ 65 years, in the respiratory department. Results There were 320 vaccinated patients, of which 164 were diagnosed with pneumococcal pneumonia. The adjusted odds ratio was 0.39 (95% confidence interval (CI), 0.17 to 0.89). In the subsets consisting of age groups ≥ 70 and ≥ 75 years, the adjusted odds ratio (95% CI) was respectively 0.16 (0.04 to 0.67) and 0.15 (0.02 to 1.12). Conclusion This real-world study suggests that PPSV23 can be useful in preventing pneumococcal pneumonia in the elderly with chronic respiratory diseases.
机译:摘要背景,23年性肺炎球菌多糖疫苗(PPSV23)预防肺炎球菌肺炎的有效性一直存在争议。方法以评价慢性呼吸系统疾病老年人门诊患者PPSV23的有效性,我们进行了病例对照研究,包括4128名≥65岁,呼吸系统。结果有320名疫苗患者,其中164例被诊断患有肺炎球菌肺炎。调整后的差距为0.39(95%置信区间(CI),0.17至0.89)。在由年龄组组成的子集中≥70和≥75岁,调整后的差距(95%CI)分别为0.16(0.04至0.67)和0.15(0.02至1.12)。结论这项现实研究表明,PPSV23可用于预防老年人患有慢性呼吸系统疾病的肺炎球菌肺炎。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号